Angeli Landeros-Weisenberger, MD
Cards
About
Titles
Associate Research Scientist
Co-chair Pediatric Protocol Review Committee, Yale Center for Clinical Investigation (YCCI); Member of the FAC executive committee, Yale School of Medicine; Member Human Investigation Committee 4-B, Yale HRPP; Faculty At Large, Educational Policy and Curriculum Committee Members
Biography
Dr. Landeros-Weisenberger graduated medicine from La Salle University in Mexico City, Mexico; and did her training in Psychiatry at the Hospital Espanol and the Universidad Nacional Autonoma de Mexico (UNAM) in the same city. After graduating, she came to Yale University through the American Psychiatric Association (APA) Minority Training grant (PMRTP) to do her research fellowship under the mentorship of Dr. James F. Leckman at the Yale Child Study Center; focusing on novel evidence-based psychotherapeutic interventions for mental disorders cross the lifespan. She has expertise in assessment of mood disorders, Tourette syndrome, obsessive compulsive disorder, trichotillomania and anxiety disorders, among others. She also has expertise conducting and implementing clinical trials in these same conditions both with industry and NIH. She enjoys teaching medical students in these disorders and training them in evidence-based techniques. She currently serves as a Co-chair of the Pediatric Protocol Review Committee (PPRC) and is a member of the executive committee for the dean's Faculty Advisory Council (FAC)and is a member of the Associate Research Scientist (ARS) and DEI subcommittees. She is a member of the Yale Human Investigation Committee 4-B and an elected voting member for the EPCC. She is a mother of three and is constantly searching for the ever-elusive work-life balance.
Appointments
Child Study Center
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Associate
- Yale University (2012)
- Postdoctoral Research Fellow
- Yale University (2009)
- Psychiatry
- UNAM (2006)
- MD
- Facultad Mexicana de Medicina La Salle University (1999)
Board Certifications
Psychiatry
- Certification Organization
- Mexico Board
Research
Publications
2024
Racial Implicit Associations in Child Psychiatry
Malison K, Avila-Quintero V, Al-Mateen C, Flores J, Landeros-Weisenberger A, Njoroge W, Novins D, Robles-Ramamurthy B, Taylor J, Bloch M, Tobón A. Racial Implicit Associations in Child Psychiatry. Journal Of The American Academy Of Child & Adolescent Psychiatry 2024 PMID: 38823476, DOI: 10.1016/j.jaac.2024.04.013.Peer-Reviewed Original ResearchImplicit Association TestRace Implicit Association TestRecruitment of human participantsExternalizing behavior problemsPaper self-identifiesImplicit associationsChildren faceBehavior problemsChild psychiatryAbstractText Label="DIVERSITY &Negatively valenced wordsExternal wordHuman participantsValenced wordsExternalizing disordersParticipating psychiatristsPsychiatric cliniciansNegative valenceNegative wordsPsychiatristsAssociation TestPsychiatryInvestigate psychiatristsReduce racial inequalityDemographic predictorsAn evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis
Ramakrishnan D, Farhat L, Vattimo E, Levine J, Johnson J, Artukoglu B, Landeros-Weisenberger A, Zangen A, Pelissolo A, de B Pereira C, Rück C, Costa D, Mataix-Cols D, Shannahoff-Khalsa D, Tolin D, Zarean E, Meyer E, Hawken E, Storch E, Andersson E, Miguel E, Maina G, Leckman J, Sarris J, March J, Diniz J, Kobak K, Mallet L, Vulink N, Amiaz R, Fernandes R, Shavitt R, Wilhelm S, Golshan S, Tezenas du Montcel S, Erzegovesi S, Baruah U, Greenberg W, Kobayashi Y, Bloch M. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. Journal Of Psychiatric Research 2024, 173: 387-397. PMID: 38598877, DOI: 10.1016/j.jpsychires.2024.03.044.Peer-Reviewed Original ResearchConceptsYale-Brown Obsessive-Compulsive ScaleObsessive-compulsive disorderCGI-IRandomized-controlled trialsAdult obsessive-compulsive disorderClinical Global Impression ImprovementObsessive-Compulsive ScaleTreatment responseIndividual-patient data meta-analysisPosttreatment scoresEvaluation of treatment responseMeta-analysis of randomized-controlled trialsFirst-line therapyCGIIndividual participant dataMeta-analysisNovel treatment modalitiesExpert consensusIndividual participant data meta-analysisSystematic reviewDisordersData meta-analysisPosttreatmentRemission definitionsImpressive improvement
2022
Characterization of human basal ganglia organoids
Brady M, Mariani J, Koca Y, Szekely A, King R, Bloch M, Landeros-Weisenberger A, Leckman J, Vaccarino F. Characterization of human basal ganglia organoids. Molecular Psychiatry 2022, 27: 4823-4823. PMID: 36536052, DOI: 10.1038/s41380-022-01914-y.Peer-Reviewed Original ResearchComparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychotic drugsMedication categoriesAntipsychotic drugsModerate certaintyIndividual medicationsTourette syndromePharmacological interventionsLow certaintyWHO International Clinical Trials Registry PlatformInternational Clinical Trials Registry PlatformSystematic reviewClinical Trials Registry PlatformChoice of medicationCochrane Central RegisterNetwork meta-analysis frameworkTrials Registry PlatformRandom-effects networkTerms of tolerabilityCertainty of evidenceClinical practice guidelinesComorbid attention deficit hyperactivity disorderStandardised mean differenceTreatment of childrenAttention deficit hyperactivity disorderWeb of ScienceMispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids
Brady M, Mariani J, Koca Y, Szekely A, King R, Bloch M, Landeros-Weisenberger A, Leckman J, Vaccarino F. Mispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids. Molecular Psychiatry 2022, 27: 5007-5019. PMID: 36447010, PMCID: PMC9949887, DOI: 10.1038/s41380-022-01880-5.Peer-Reviewed Original ResearchConceptsTourette syndromeInterneuron deficitsGABAergic interneuronsHealthy controlsNeurodevelopmental underpinningsNeuropathological deficitsBG circuitryNeuropsychiatric disordersDecreased differentiationT patientsInterneuronsAltered expressionPotential mechanismsCilia disruptionSonic hedgehogOrganoidsStem cellsTS individualsPluripotent stem cellsGli transcription factorsDeficitsOrganoid differentiationEarly stagesCholinergicPatientsEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionComprehensive Assessment Strategies
King R, Landeros-Weisenberger A. Comprehensive Assessment Strategies. 2022, 335-342. DOI: 10.1093/med/9780197543214.003.0020.Peer-Reviewed Original ResearchMeta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders
Behling E, Farhat LC, Landeros‐Weisenberger A, Bloch MH. Meta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. Movement Disorders 2022, 37: 684-693. PMID: 35191552, DOI: 10.1002/mds.28957.Peer-Reviewed Original ResearchConceptsChronic tic disorderTourette syndromeVMAT2 inhibitorsTic disordersVesicular monoamine transporter type 2 inhibitorsYale Global Tic Severity ScaleMean differenceRate of discontinuationTic Severity ScaleType 2 inhibitorsShort-term treatmentTic symptomsBlinded RCTEffective therapySeverity ScaleSystematic reviewTolerabilityAvailable evidenceAdverse effectsInverse varianceEfficacyRCTsInhibitorsNonsignificant effectTrials
2021
Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder
Farhat LC, Vattimo EFQ, Ramakrishnan D, Levine JLS, Johnson JA, Artukoglu BB, Landeros-Weisenberger A, Asbahr FR, Cepeda SL, Comer JS, Fatori D, Franklin ME, Freeman JB, Geller DA, Grant PJ, Goodman WK, Heyman I, Ivarsson T, Lenhard F, Lewin AB, Li F, Merlo LJ, Mohsenabadi H, Peris TS, Piacentini J, Rosa-Alcázar AI, Rosa-Alcázar À, Rozenman M, Sapyta JJ, Serlachius E, Shabani MJ, Shavitt RG, Small BJ, Skarphedinsson G, Swedo SE, Thomsen PH, Turner C, Weidle B, Miguel EC, Storch EA, Mataix-Cols D, Bloch MH. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 61: 495-507. PMID: 34597773, DOI: 10.1016/j.jaac.2021.05.027.Peer-Reviewed Original ResearchConceptsPediatric obsessive-compulsive disorderObsessive-compulsive disorderOptimal cutoffYale-Brown ObsessiveCY-BOCSClinical trialsSystematic reviewClinical Global Impression-ImprovementRandom-effects meta-analysis modelDiscriminative abilityStandardized operational definitionsMeta-analysis modelChildren's Yale-Brown ObsessiveDiagnostic test accuracyTreatment responseRemissionSeverity ScaleMeta-AnalysisYouden indexCompulsive ScaleTrialsDisordersA Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
Clinical Trials
Current Trials
PET and MRI in OCD and/or Tic disorders
HIC ID2000021811RoleSub InvestigatorPrimary Completion Date11/30/2018Recruiting ParticipantsBrain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)
HIC ID0407026910RoleSub InvestigatorPrimary Completion Date06/30/2022Recruiting ParticipantsGenderBothAge16 years - 24 years
Academic Achievements and Community Involvement
Links & Media
News
- April 23, 2024Source: The UpTic Podcast
Research-based Treatment of Tics, OCD, and Depression
- October 03, 2023
Over 150 Attend Yale Child Study Center In-house Open House
- May 04, 2023
April 2023 YCSC Faculty Development Fund Awardees Announced
- October 12, 2022Source: Newsweek
Forget Weed, Wine and Xanax: Science Has Better Ways to Treat Anxiety